23 results on '"Wang, Zhiping"'
Search Results
2. Knockdown of AMIGO2 suppresses proliferation and migration through regulating PPAR-γ in bladder cancer
- Author
-
Han, Dali, Xiong, Bin, Zhang, Xiangxiang, Chen, Chaohu, Yao, Zhiqiang, Wu, Hao, Cao, Jinlong, Li, Jianpeng, Li, Pan, Wang, Zhiping, and Tian, Junqiang
- Published
- 2024
- Full Text
- View/download PDF
3. Perioperative outcomes and continence following robotic-assisted radical cystectomy with mainz pouch II urinary diversion in patients with bladder cancer
- Author
-
Jing, Suoshi, Yang, Enguang, Luo, Zuoxi, Zhang, Yunxin, Ding, Hui, Yang, Li, Dong, Zhilong, Shang, Panfeng, Yue, Zhongjin, Wu, Gongjin, Bao, Junsheng, Tian, Junqiang, Wang, Jiaji, Xiao, Nan, and Wang, Zhiping
- Published
- 2024
- Full Text
- View/download PDF
4. Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis
- Author
-
Lu, Lanpeng, Chen, Chaohu, Cheng, Hui, Ding, Hui, Tian, Junqiang, Wang, Hanzhang, and Wang, Zhiping
- Published
- 2023
- Full Text
- View/download PDF
5. ADAM12 promotes gemcitabine resistance by activating EGFR signaling pathway and induces EMT in bladder cancer
- Author
-
Wang, Runchang, Gao, Dongyang, Chen, Chaohu, Fan, Guangrui, Cheng, Hui, Tao, Yan, Lu, Jianzhong, Tian, Junqiang, Wang, Yuhan, and Wang, Zhiping
- Published
- 2023
- Full Text
- View/download PDF
6. Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial
- Author
-
Li, Rongxin, Li, Ye, Song, Jun, Gao, Ke, Chen, Kangning, Yang, Xiaogang, Ding, Yongqiang, Ma, Xinlong, Wang, Yang, Li, Weipeng, Wang, Yanan, Wang, Zhiping, and Dong, Zhilong
- Published
- 2020
- Full Text
- View/download PDF
7. Is Anti-Reflux Anastomosis an Advantage in an Orthotopic Ileal Neobladder? A Systematic Review and Meta-Analysis.
- Author
-
Zhang, Yuanfeng, Ding, Hui, Zhang, Yunxin, Tian, Junqiang, Yang, Li, Dong, Zhilong, Wang, Juan, Wang, Yuhan, Zhang, Yonghai, and Wang, Zhiping
- Subjects
URINARY diversion ,ILEAL conduit surgery ,VESICO-ureteral reflux ,SURGICAL stents ,OPERATIVE surgery ,ODDS ratio ,BLADDER cancer - Abstract
Introduction: We conducted a systematic review and meta-analysis to assess the available literature regarding the postoperative effects of anti-reflux anastomosis and direct anastomosis in orthotopic ileal neobladder (ONB). Methods: We searched PubMed, Embase, and the Cochrane Library in October 2021. We included 11 studies of patients with bladder cancer who underwent radical cystectomy and ONB as urinary diversion. Outcomes evaluated in this review were ureteroenteric anastomotic stricture (UEAS), vesicoureteral reflux, renal function (RFn) impairment, and pyelonephritis. All data were analyzed using Review Manager 5.4.4 and subgroup analyses were applied. Results: A total of 11 studies were eligible for meta-analysis. The synthetic data suggested that anti-reflux anastomosis and direct anastomosis were comparable in terms of RFn impairment (odds ratio (OR) = 1.69; 95% confidence interval (CI): 0.18–15.6; p = 0.65, I
2 = 69%) and pyelonephritis (OR = 1.13; 95% CI: 0.65–1.99; p = 0.66, I2 = 1%) without significant difference in each group statistically. The pooled study data showed a significantly higher incidence of UEAS (OR = 2.84; 95% CI: 1.75–4.61, p < 0.0001, I2 = 50%) and a lower incidence of vesicoureteral reflux (OR = 0.24; 95% CI: 0.10–0.59; p = 0.002, I2 = 75%) in anti-reflux anastomosis compared to direct anastomosis. In subgroup analysis, anti-reflux anastomosis was more likely to result in UEAS than direct anastomosis, especially when ureteral stent was removed within 14 days. Conclusion: Although meta-analysis showed that overall incidence of vesicoureteral reflux was higher with direct anastomosis than anti-reflux anastomosis, the rate of vesicoureteral reflux was not directly related to impairment of RFn. The anti-reflux mechanism of ONB was positively associated with a higher incidence of significant UEAS compared to the direct approach, which can lead to kidney damage and an increased risk of secondary surgical procedures. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
8. Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro
- Author
-
Wang, Li, Zhang, Yunxin, Zhao, Jinxia, Xiao, Erlong, Lu, Jianzhong, Fu, Shengjun, and Wang, Zhiping
- Published
- 2014
- Full Text
- View/download PDF
9. Prognostic value of preoperative platelet-related parameters and plasma fibrinogen in patients with non-muscle invasive bladder cancer after transurethral resection of bladder tumor.
- Author
-
Song, Yutong, Tian, Junqiang, Yang, Li, Zhang, Yunxin, Dong, Zhilong, Ding, Hui, Wang, Juan, Wang, Yuhan, Wang, Hanzhang, and Wang, Zhiping
- Subjects
CYSTECTOMY ,PLATELET lymphocyte ratio ,TRANSURETHRAL resection of bladder ,CANCER relapse ,NON-muscle invasive bladder cancer ,FIBRINOGEN ,PLATELET count - Abstract
Aim: To investigate the prognostic value of preoperative mean platelet volume (MPV), MPV/lymphocyte ratio (MPVLR), MPV/platelet count ratio and plasma fibrinogen in patients with non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT). Methods: A total of 371 patients who underwent TURBT were enrolled. The main end points were disease-free survival (DFS) and overall survival (OS). Results: MPVLR, tumor size, tumor number and pathological grade were independent risk factors for postoperative DFS. Age and pathological grade were independent risk factors for postoperative OS. Conclusion: MPVLR is an independent risk factor for DFS in NMIBC patients and could be used as a parameter to predict postoperative tumor recurrence in patients after TURBT. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Y-Box Binding Protein 1 Regulates Angiogenesis in Bladder Cancer via miR-29b-3p-VEGFA Pathway.
- Author
-
Gao, Dongyang, Niu, Qian, Gong, Yuwen, Guo, Qi, Zhang, Su, Wang, Yuhan, Liu, Shanhui, Wang, Hanzhang, Svatek, Robert, Rodriguez, Ronald, Ma, Junhai, and Wang, Zhiping
- Subjects
CARRIER proteins ,VASCULAR endothelial growth factors ,BLADDER cancer ,NEOVASCULARIZATION - Abstract
Angiogenesis plays a vital role in the development of bladder cancer (BC). The Y-box-binding protein 1 (YB-1) is a well-known oncoprotein which is closely related to angiogenesis of tumors, but the relationship and mechanism of YB-1 and angiogenesis in BC remain unclear. Based on 56 clinical BC specimens, this study found that high expression of YB-1 samples demonstrated a higher expression of vascular endothelial growth factor A (VEGFA) than those of YB-1 low expression. Subsequently, the expression of YB-1 and miR-29b-3p was regulated in the BC cell lines where we noted that YB-1 promoted VEGFA expression by downregulating the expression of miR- 29b-3p. The ability of BC cells to induce angiogenesis decreased after YB-1 was knocked down. Moreover, the in vivo study further confirmed that YB-1 promotes angiogenesis in BC. Our findings enhance the understanding of how YB-1 promotes angiogenesis in BC and provide evidence for YB-1 as a therapeutic target of BC. Moreover, this may provide new inspiration for miRNAs replacement therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Circulating Tumor DNA Analyses Predict Disease Recurrence in Non-Muscle-Invasive Bladder Cancer.
- Author
-
Zhang, Jinghua, Dai, Daofeng, Tian, Junqiang, Li, Lifeng, Bai, Jing, Xu, Yaping, Wang, Zhiping, and Tang, Aifa
- Subjects
BLADDER cancer ,CIRCULATING tumor DNA ,DISEASE relapse ,DNA analysis - Abstract
Circulating tumor DNA (ctDNA) can be a prognostic biomarker for non-muscle-invasive bladder cancer (NMIBC); however, targeted sequencing has not been performed to detect ctDNA in NMIBC. We applied targeted sequencing based on an 861-gene panel to determine mutations in tumor tissue DNA and plasma ctDNA in 82 NMIBC patients receiving transurethral resection (TUR) of bladder followed by immunotherapy. We detected 476 and 165 somatic variants in tumor DNA from 82 NMIBC patients (100%) and ctDNA from 54 patients (65.85%), respectively. Patients with high heterogeneity in tumor DNA had a significantly shorter disease-free survival than those with low heterogeneity. Tumor-derived alterations were detectable in plasma of 43 patients (52.44%). The concordance of somatic variants between tumor DNA and plasma ctDNA were higher in patients with T1 stage (p < 0.0001) and tumor size ≥3 cm (p = 0.0002). Molecular tumor burden index (mTBI) in ctDNA positively correlated with larger tumor size (p = 0.0020). A higher mTBI was an independent predictor of recurrence after TUR of bladder followed by immunotherapy. Analysis of ctDNA based on targeted sequencing is a promising approach to predict disease recurrence for NMIBC patients receiving TUR of bladder followed by immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Comparison of open and intracorporeal modified ureterosigmoidostomy (Mainz II) after laparoscopic radical cystectomy with bladder cancer.
- Author
-
Zheng, Duo, Liu, Junyao, Wu, Gongjin, Yang, Shujun, Luo, Chuang, Du, Tianci, Luo, Yao, Bao, Junsheng, Tian, Junqiang, Wang, Zhiping, Shang, Panfeng, and Yue, Zhongjin
- Subjects
INTRAVESICAL administration ,BLOOD loss estimation ,CYSTECTOMY ,BLADDER cancer ,URINARY diversion ,LAPAROSCOPIC surgery ,PROGRESSION-free survival - Abstract
Objective: To compare perioperative and oncologic outcomes of open modified ureterosigmoidostomy urinary diversion (OMUUD) and intracorporeal modified ureterosigmoidostomy urinary diversion (IMUUD) following laparoscopic radical cystectomy (LRC). Patients and methods: We retrospectively reviewed our single institutional collected database patients undergoing LRC from October 2011 to October 2019. The perioperative characteristics were compared between OMUUD and IMUUD, and overall survival (OS) and progression-free survival (PFS) were evaluated by the Kaplan-Meier method. Results: Overall, 84 patients were included. OMUUD and IMUUD were performed in 63 (75%) and 21 (25%) patients, respectively. IMUUD patients demonstrated shorter postoperative length of stay (16.24 ± 3.91 days vs. 18.98 ± 7.41 days, P = 0.033), similar operation time (498.57 ± 121.44 vs. 462.24 ± 99.71, P = 0.175), similar estimated blood loss [400 (200–475) ml vs. 400 (200–700) ml, P = 0.095], and similar overall complication rate within 30 days (19.05% vs. 25.40%, P = 0.848) and 90 days (23.81% vs. 17.46%, P = 0.748). Complete urinary control rate was 87.3% (55/63) in the OMUUD group. In IMUUD, the complete urinary control rate was 90.5% (19/21). There was no significant difference in OS (χ
2 = 0.015, P = 0.901) and PFS (χ2 = 0.107, P = 0.743) between the two groups. Conclusion: IMUUD postoperative recovery is faster; other perioperative outcomes and oncology results are not significantly different with OMUUD. It is indicated that IMUUD can be utilized safely and effectively in the urinary diversion after LRC. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
13. rAAV9-UPII-TK-EGFP can precisely transduce a suicide gene and inhibit the growth of bladder tumors.
- Author
-
Lian, Foyan, Ye, Qiang, Feng, Bing, Cheng, Hui, Niu, Shaomin, Fan, Ning, Wang, Degui, and Wang, Zhiping
- Subjects
BLADDER cancer ,TUMOR growth ,DRUG delivery systems ,GENE therapy ,CELL membranes ,ADENO-associated virus - Abstract
Bladder cancer is a common and widespread cancer of the human urinary system, and its incidence is increasing. Gene therapy is a promising treatment of bladder cancer. In our study, a recombinant adeno-associated virus (rAAV9-UPII-TK-EGFP) driven by a UPII promoter was constructed. The efficacy and safety of infection of bladder cells was tested in vivo and in vitro. The ability of rAAV9-UPII-TK-EGFP to penetrate the glycosaminoglycan (GAG) layer on the surface of bladder cells and to transduce the bladder cells in vivo was very high. Additionally, we confirmed that the TK/GCV system has a powerful cytotoxic effect on bladder tumor cells in vitro and in vivo. Thus, our data indicate that rAAV9-UPII-TK-EGFP is a precise gene drug delivery system for the treatment of bladder cancer, and the TK/GCV therapeutic strategy has a powerful antitumor effect. These findings can be widely used in clinical and scientific studies. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Identification of prognostic biomarkers associated with stromal cell infiltration in muscle‐invasive bladder cancer by bioinformatics analyses.
- Author
-
Li, Pan, Cao, Jinlong, Li, Jianpeng, Yao, Zhiqiang, Han, Dali, Ying, Lijun, Wang, Zhiping, and Tian, Junqiang
- Subjects
STROMAL cells ,BLADDER cancer ,RECEIVER operating characteristic curves ,CELLULAR control mechanisms ,BIOMARKERS - Abstract
Muscle‐invasive bladder cancer (MIBC) is one of the common malignant tumors. Patients with MIBC still have high tumor recurrence and progression rates after surgery. Bioinformatics analysis of stromal infiltration‐related genes in the tumor microenvironment (TME) of MIBC patients was performed in this study to determine the major stromal cells types and biomarkers for their progression and poor prognosis. The ESTIMATE algorithm was applied to evaluate the stromal score and immune score of samples from MIBC patients in The Cancer Genome Atlas (TCGA) and found that stromal score was closely related to the clinical characteristics of the patients. The Gene Set Enrichment Analysis (GSEA) further revealed that stromal cells were involved in biological processes such as activation of leukocytes and positive regulation of cell migration during MIBC progression, as well as PI3K‐Akt, MAPK, and Rap1 signaling pathways. Five hub genes related to prognosis, including ACTA2, COL5A1, DCN, LUM, and PRRX1 were identified by the Weighted Gene Co‐Expression Network Analysis (WGCNA), Protein‐Protein Interaction (PPI), survival analysis, and Oncomine, Gene Expression Omnibus (GEO) database validation. Besides, we identified five stromal cell types associated with overall survival time, among which chondrocytes and fibroblasts were identified as the major stromal cell types through correlation analysis. Finally, the Receiver Operating Characteristic (ROC) curve and immunohistochemistry were used to verify the diagnostic value and expression of hub genes in different invasive tumors. In summary, we investigated the biological behavior of stromal cells in the TME of MIBC to promote tumor progression obtained hub genes associated with progression and poor prognosis and identified the main stromal cells types in the TME. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. AB087. The biotherapy for bladder cancer
- Author
-
Wang, Zhiping
- Subjects
Bladder cancer ,biotherapy ,BCG ,Podium Lecture - Abstract
The high frequency of recurrence and poor survival rate of bladder cancer demand exploration of novel strategies. Biotherapy strategies include immunotherapy, gene therapy, inducing cell apoptosis, and so on. Precious studies indicated that BCG could effectively prevent tumor recurrence, and significantly reduce tumor progression. Our studies showed that BCG combined with epirubicin could more effectively inhibit tumor recurrence and progression. But BCG also has its own side effects. Studies showed that Wan Te Puan induce tumor cell apoptosis by inhibit EGFR signaling pathway, and induce the conversion of macrophage and dendritic cells activation through improving immune microenvironment. We demonstrated that modified DC by cytokines has better antitumor effect. Promisingly, our group constructed a bladder cancer-specific adenovirus carrying E1A-androgen receptor (AR) under the control of UPII promoter and prostate stem cell antigen enhancer (PSCAE), designated as Ad/PSCAE/UPII/E1A-AR, and investigated its antitumor effects in vitro and in vivo. We demonstrated that Ad/PSCAE/UPII/E1A-AR could be selectively replicated in bladder tumor cell lines (5637, BIU87, EJ and T24) when compared with control adenovirus Ad/PSCAE/UPII/Luc. In addition, we demonstrated that intratumoral injection of Ad/PSCAE/UPII/E1A-AR into established subcutaneous human EJ tumors in nude mice could significantly regress the growth of tumor and markedly prolong survival for tumor-bearing mice; on the other hand, saline-treated tumors continued to grow rapidly. Importantly, there is no evidence of cytotoxicity for normal human bladder cell line SVHUC-1 and hepatoma cell line SMMC7721. Our study also showed that radiotherapy and chemotherapy synergistically enhanced the antitumor effect of oncolytic adenovirus. We found that recombinant adenovirus Ad/PSCAE/UPII/E1A-AR appear safe with 5×107 pfu and 5×108 pfu intratumorally injection in mice, without any discernable effects on general health and behavior. Furthermore, our findings provide a promising therapeutic modality for the treatment of bladder cancer.
- Published
- 2015
16. Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells.
- Author
-
Zhang, Hongjuan, Wang, Fang, Mao, Chunjie, Zhang, Zuncheng, Fu, Shengjun, Lu, Jianzhong, Zhai, Zhenxing, Li, Renju, Li, Shuwen, Rodriguez, Ron, and Wang, Zhiping
- Subjects
BLADDER cancer treatment ,RADIOTHERAPY ,CANCER cells ,ADENOVIRUSES ,DNA viruses - Abstract
Purpose:Gene therapy combined with radiation has shown promising potential for the treatment of tumors. This paper aimed to clarify the synergistic effect of radiotherapy combined with the bladder cancer tissue-specific oncolytic adenovirus (Ad-PSCAE-UPII-E1A) on bladder cancer cells and to study the underlying synergy mechanisms of the combined treatment. Materials and methods:The Adenovirus carrying E1A under control of UPII promoter and prostate stem cell antigen enhancer (PSCAE) were successfully constructed. The viability of bladder cancer cells BIU-87 and EJ was determined by MTT assay. The apoptotic assay was demonstrated by flow cytometry and TEM. Virus titer was determined by TCID50 assay, and proteins Mre11, Chk2-Thr68, and E1A were analyzed by Western blot method. Results:Oncolytic adenovirus combined with radiotherapy improved antitumor efficacy compared with the single treatment at a time and was X-ray dosage-dependent. When the adenovirus infection was scheduled at 24 h after irradiation, cancer cells had the lowest viability. Adenovirus and irradiation induced cell death through the caspase-3 related apoptotic pathway, and bladder cancer cells were arrested at the G1 (BIU-87) or S phase (EJ). Autophagic vacuoles were observed in bladder cancer cells treated with radiation and adenovirus. After irradiation, more virus particles were observed in the BIU-87 and EJ cells. However, by a TCID50 assay, there was no difference in virus titter between irradiated bladder cancer cells and unirradiated cells. The proteins Mre11, Chk2-Thr68 which involved in the DNA break repair pathway were decreased while γ-H2AX-Ser139 increased; at the same time, the E1A gene and the hexon proteins of oncolytic adenovirus were increased after irradiation. Conclusions:Our results proved synergistic antitumor effect of adenovirus Ad-PSCAE-UPII-E1A and radiation, which might be a potential therapeutic strategy for bladder cancer. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
17. Clinicopathological and Prognostic Value of Ki-67 Expression in Bladder Cancer: A Systematic Review and Meta-Analysis.
- Author
-
Tian, Yuejun, Ma, Zhiming, Chen, Zhaohui, Li, Mingguo, Wu, Zhiping, Hong, Mei, Wang, Hanzhang, Svatek, Robert, Rodriguez, Ronald, and Wang, Zhiping
- Subjects
BLADDER cancer ,KI-67 antigen ,GENE expression ,TUMOR markers ,CLINICAL pathology ,SYSTEMATIC reviews ,PROGNOSIS - Abstract
Background: Ki-67 is an established marker of cell proliferation, and the Ki-67 index correlates with the clinical course of several cancer types, including bladder cancer (BC). However, the clinicopathological and prognostic significance of Ki-67 in bladder cancer remains unclear. Therefore, we performed a systematic review and meta-analysis to clarify this relationship. Methods: A comprehensive literature search for relevant studies published up to February 1, 2016, was performed using PubMed, Cochrane Library, Embase and ISI Web of Knowledge. The effects of Ki-67 expression on survival outcome in patients with BC and BC subtypes were evaluated. Furthermore, the relationship between Ki-67 expression and the clinicopathological features of BC were assessed. Results: Thirty-one studies with 5147 bladder cancer patients were selected for evaluation. Ki-67 expression was significantly associated with shorter recurrence-free (HR 1.69, 95% CI: 1.33–2.14), progression-free (HR 1.89, 95% CI: 1.43–2.51), overall (HR 2.03, 95% CI: 1.31–3.16), and cancer-specific (HR 1.69, 95% CI: 1.47–1.95) survival. Moreover, whereas high expression was more common in high tumor stage, recurrence status, tumor size, there was no correlation between high Ki-67 expression and age, gender, smoking habits, and tumor number. Importantly, analysis of the different subgroups of BC suggested that significant correlations between high Ki-67 expression and survival outcome (recurrence-free/progression-free/overall/cancer-specific survival) are present only in European-American patients. Conclusion: The present results indicate that over-expression of Ki-67 is distinctly correlated with poor patient survival. Ki-67 may serve as a valuable biomarker for prognosis in BC patients, particularly in non-Asian BC patients. The results suggest no significant association between Ki-67 expression and BC prognosis in Asian patients. Further efforts are needed to fully clarify this relationship. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
18. Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector
- Author
-
Wang, Degui, Wang, Zhiping, Tian, Junqiang, He, Xiangdong, Chowdhury, Wasim H., Zhang, Xiangbo, Li, Shigang, and Rodriguez, Ronald
- Subjects
- *
CANCER treatment , *GENE therapy , *BLADDER cancer , *CELL surface antigens , *GENETIC vectors , *PROMOTERS (Genetics) , *POLYMERASE chain reaction , *PLASMIDS , *LUCIFERASES - Abstract
Abstract: Purpose: To construct a dual specific vector which contains prostate stem cell antigen enhancer (PSCAE) and uroplakin II (UPII) promoter targeted bladder cancer. Methods: UPII promoter and PSCAE were amplified by polymerase chain reaction (PCR). Luciferase gene (LUC) was obtained from plasmid pBK-CMV-LUC. PSCAE, UPII promoter and LUC were inserted into shuttle plasmid to create Rp-UPII-LUC and Rp-PSCAE-UPII-LUC. Rp-UPII-LUC and Rp-PSCAE-UPII-LUC were cotransfected with pCMV-β-gal into various cell lines at the presence or absence of androgen receptor agonist R1881 and androgen receptor antagonist flutamide. Luminescence was detected with luciferase assay kit and counted on liquid scintillation counter. Results: Bladder cancer cells showed higher LUC activity than non-bladder cancer cells after transfected with plasmids Rp-UPII-LUC and Rp-PSCAE-UPII-LUC. PSCAE could improve the LUC activity in both AR positive and AR negative bladder cancer cells but not in non-bladder cancer cells and normal human urothelial (NHU) cells. R1881 could increase the LUC activity in AR positive bladder cancer cells but not in AR negative bladder cancer cells and non-bladder cancer cells. Flutamide could not inactivate PSCAE in bladder cancer cells. Conclusions: PSCAE can improve target gene expression in bladder cancer cells but not in non-bladder cancer cells and NHU cells. PSCAE maintains a certain level of androgen independent activity in bladder cancer cells. PSCAE is active in both AR positive and AR negative bladder cancer cells. The results suggest that combination of PSCAE with UPII promoter is feasible in constructing bladder cancer-specific vectors. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
19. Effects of curcumin on bladder cancer cells and development of urothelial tumors in a rat bladder carcinogenesis model
- Author
-
Tian, Binqiang, Wang, Zhiping, Zhao, Yingmei, Wang, Degui, Li, Yonggang, Ma, Li, Li, Xiaoming, Li, Jing, Xiao, Nan, Tian, Junqiang, and Rodriguez, Ronald
- Subjects
- *
BLADDER cancer , *CANCER cells , *CARCINOGENESIS , *ANIMAL models in research - Abstract
Abstract: Curcumin, a well-known dietary pigment derived from Curcuma longa, inhibited growth of several types of malignant cells both in vivo and in vitro. Its effects on cell proliferation and the induction of apoptosis in human bladder cancer cell lines and intravesical activity in a rat bladder tumor model were studied. Exposure of human bladder cancer cells to curcumin resulted in the induction of apoptotic cell death and caused cells to arrest in the G2/M phase. The anti-apoptotic Bcl-2 and Survivin protein was downregulated by the curcumin treatment together with enhancement of the Bax and p53 expression. The inhibitory activities of curcumin were stronger than those of cisplatin and could not be prevented by catalase pretreatment in T24 cells. Clonal assay indicated large-dose and short-term curcumin was lethal to bladder cancer cells. Moreover, the in vivo study revealed curcumin did induce apoptosis in situ, inhibit and slow the development of bladder cancer. These observations suggest that curcumin could prove an effective chemopreventive and chemotherapy agent for bladder cancer. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
20. CAB39 promotes cisplatin resistance in bladder cancer via the LKB1-AMPK-LC3 pathway.
- Author
-
Gao, Dongyang, Wang, Runchang, Gong, Yuwen, Yu, Xiaoquan, Niu, Qian, Yang, Enguang, Fan, Guangrui, Ma, Junhai, Chen, Chaohu, Tao, Yan, Lu, Jianzhong, and Wang, Zhiping
- Subjects
- *
CISPLATIN , *BLADDER cancer , *REACTIVE oxygen species , *CANCER invasiveness - Abstract
Systemic therapy for muscle-invasive bladder cancer (BC) remains dominated by cisplatin-based chemotherapy. However, resistance to cisplatin therapy greatly limits long-term survival. Resistance to cisplatin-based chemotherapy still needs to be addressed. In this study, we established three cisplatin-resistant BC cell lines by multiple cisplatin pulse treatments. Interestingly, after exposure to cisplatin, all cisplatin-resistant cell lines showed lower reactive oxygen species (ROS) levels than the corresponding parental cell lines. Using proteomic analysis, we identified 35 proteins that were upregulated in cisplatin-resistant BC cells. By knocking down eleven of these genes, we found that after CAB39 knockdown, BC cisplatin-resistant cells were more sensitive to cisplatin. Overexpression of CAB39 had the opposite effect. Then, the knockdown of six genes downstream of CAB39 revealed that CAB39 promoted cisplatin resistance in BC through LKB1. Moreover, a key cause of cisplatin-induced cell death is damage to mitochondria and increased ROS levels. In our study, cisplatin-resistant cells exhibited higher autophagic flux and healthier mitochondrial status after cisplatin exposure. We demonstrated that the CAB39-LKB1-AMPK-LC3 pathway plays a critical role in enhancing autophagy to maintain the health of mitochondria and reduce ROS levels. In addition, the autophagy inhibitor chloroquine (CQ) can significantly enhance the killing effect of cisplatin on BC cells. Compared with gemcitabine plus cisplatin (GC), GC plus CQ significantly reduced tumor burden in vivo. In conclusion, our study shows that CAB39 counteracts the killing of cisplatin by enhancing the autophagy of BC cells to damaged mitochondria and other organelles to alleviate the damage of cells caused by harmful substances such as ROS. [Display omitted] • Cisplatin-resistant bladder cancer cells have enhanced autophagic flux and healthier mitochondrial status. • The expression of CAB39 in cisplatin-resistant bladder cancer cells is higher than that in their parents. • CAB39 promotes cisplatin resistance in bladder cancer via the LKB1-AMPK-LC3 pathway. • The autophagy inhibitor chloroquine promotes the sensitivity of bladder cancer cells to cisplatin. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Modulation of Nitric Oxide on Lymphokine-activated Killer Cells in Patients with Bladder Cancer.
- Author
-
Wang Zhiping, Fu Shengjun, Chen Yirong, and Qin Dashan
- Subjects
- *
NITRIC oxide , *LYMPHOKINES , *BLADDER cancer - Abstract
Examines the role of nitric oxide in the activation of lymphokine-activated killer (LAK) cells among patients with bladder cancer in China. Cytotoxicity of LAK cells; Determination of the activity of nitric oxide synthase in LAK cells; Inhibition of sodium nitroprusside.
- Published
- 2001
22. SRT1720 inhibits bladder cancer cell progression by impairing autophagic flux.
- Author
-
Li, Lanlan, Fu, Shengjun, Wang, Jianliang, Lu, Jianzhong, Tao, Yan, Zhao, Liangtao, Fu, Beitang, Lu, Lanpeng, Xiang, Caifei, Sun, Xince, Liu, Shanhui, Wang, Degui, and Wang, Zhiping
- Subjects
- *
BLADDER cancer , *LYSOSOMES , *CANCER invasiveness , *CANCER cell growth , *CANCER cells , *CANCER cell migration , *URODYNAMICS - Abstract
[Display omitted] Bladder cancer (BC) is the most common cancer of the urinary tract, with poor survival, high recurrence rates, and lacking of targeted drugs. In this study, we constructed a library to screen compounds inhibiting bladder cancer cells growth. Among them, SRT1720 was identified to inhibit bladder cancer cell proliferation in vitro and in vivo. SRT1720 treatment also suppressed bladder cancer cells migration, invasion and induced apoptosis. Mechanism studies shown that SRT1720 promoted autophagosomes accumulation by inducing early-stage autophagy but disturbed the late-stage of autophagy by blocking fusion of autophagosomes and lysosomes. SRT1720 appears to induce autophagy related proteins expression and alter autophagy-related proteins acetylation to impede the autophagy flux. LAMP2, an important lysosomal associated membrane protein, may mediate SRT1720-inhibited autophagy flux as SRT1720 treatment significantly deacetylated LAMP2 which may influence its activity. Taken together, our results demonstrated that SRT1720 mediated apoptosis and autophagy flux inhibition may be a novel therapeutic strategy for bladder cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Licochalcone B inhibits growth of bladder cancer cells by arresting cell cycle progression and inducing apoptosis.
- Author
-
Yuan, Xuan, Li, Tao, Xiao, Erlong, Zhao, Hong, Li, Yongqian, Fu, Shengjun, Gan, Lu, Wang, Zhenhua, Zheng, Qiusheng, and Wang, Zhiping
- Subjects
- *
CHALCONES , *BLADDER cancer , *APOPTOSIS , *CELL cycle , *CANCER cell proliferation , *MITOSIS , *ANTINEOPLASTIC agents , *IN vitro toxicity testing - Abstract
Highlights: [•] In this study, we found licochalcone B (LCB) could inhibit proliferation of T24 and EJ cells in vitro. [•] S-phase arrest and apoptosis involved in LCB’s antiproliferative effects. [•] Corresponding, we illustrated the possible mechanisms of LCB-induced S-phase arrest and apoptosis. [•] We also demonstrated the antitumor activity of LCB in vivo in MB49 (murine bladder cancer cell line) tumor model. [•] This was the first time to explore the effects of LCB on the bladder cancer cells. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.